Publisher
Springer International Publishing
Reference34 articles.
1. Alter M, Satzger I, Schrem H, Kaltenborn A, Kapp A, Gutzmer R (2014) Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients. J Dtsch Dermatol Ges 12:480–488
2. Andtbacka RHI, Kaufman HL, Collichio F et al (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33:2780–2788
3. Arnold AW, Bruckner-Tuderman L, Zuger C, Itin PH (2009) Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology 219:80–83
4. Basset-Séguin N, Hauschild A, Kunstfeld R, Grob J, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Arenberger P, Fife K, Raimundo A, Dika E, Dimier N, Fittipaldo A, Xynos I, Hansson J (2017) Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer 86:334–348
5. Breuninger H, Eigentler T, Bootz F, Hauschild A, Kortmann RD, Wolff K, Stockfleth E, Szeimies RM, Rompel R, Garbe C, Grabbe S (2013) Brief S2k guidelines – cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges 11(3):37–45